DUBLIN–(BUSINESS WIRE)–Presbia PLC (NASDAQ: LENS), an ophthalmic device company and leader in near vision restoration announced that it has scheduled the remaining treatments for completing the second stage enrollment of its U.S. Food and Drug Administration (FDA) pivotal study, a significant milestone in the FDA approval process of its Presbia Flexivue Microlens™. The final surgeries will take place the week of September 7. This announcement was made at the Barcelona 2015 XXXIII Congress of
A single-piece hydrophobic acrylic IOL was associated with a significant increase in posterior capsule opacification up to 3 years and stabilization between 3 years and 5 years, according to a study.The prospective study included 390 eyes of 390 patien…
A single-piece hydrophobic acrylic IOL was associated with a significant increase in posterior capsule opacification up to 3 years and stabilization between 3 years and 5 years, according to a study.The prospective study included 390 eyes of 390 patien…
ALAMEDA, Calif.–(BUSINESS WIRE)–InSite Vision Receives Second Unsolicited Acquisition Proposal for $0.35 per Share from a Global Pharmaceutical Company
(MedPage Today) — A searchable database of quality improvement projects may prevent duplication of efforts, suggests Fred N. Pelzman, MD
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/jb2qxk/proliferative) has announced the addition of the “Proliferative Vitreoretinopathy (PVR) – Pipeline Review, H2 2015” report to their offering. This report p…